Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Keeping Track: Provention Teplizumab, AZ Anifrolumab Headline Submissions; AZ Brilinta Gains Stroke Risk Reduction Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track Of Submissions: Myovant’s First Relugolix NDA; Merck Resubmits Longer Keytruda Dosing; Biogen Adjusts Aducanumab Rolling Target
The latest news and highlights about submissions for US approval, from the Pink Sheet FDA Performance Tracker.
Aimmune CEO Jayson Dallas tells the Pink Sheet how physicians and patients are being certified to use Palforzia and how the product's food-based manufacturing process is actually an advantage.